| Autor: |
Harjianti T; Division of Medical Hemato-oncology, Department of Internal Medicine, Hasanuddin University - Wahidin Sudirohusodo Teaching Hospital, Makassar, Indonesia. tutikheru@gmail.com., Benyamin F, Minhajat R, Saleh S, Bayu D, Pababbari W |
| Jazyk: |
angličtina |
| Zdroj: |
Acta medica Indonesiana [Acta Med Indones] 2023 Jul; Vol. 55 (3), pp. 332-338. |
| Abstrakt: |
Management of chronic myeloid leukemia (CML) in patients who are infected with COVID-19 is a challenging task due to disease-related or treatment-related factors that place such patients at a higher risk of complications. However, a low-infectivity-rate mechanism has been proposed by some researchers. In CML patients with COVID-19 infection, the most important treatment-related factor involves tyrosine kinase inhibitors (TKIs). In this case report, six patients with chronic-phase CML who experienced COVID-19 of mild-moderate severity all continued to receive TKI treatment for CML concurrently with COVID-19 treatment. All patients fully recovered. In the present study, we also review four other cases of COVID-19 infection in CML patients. Outcomes for TKI-treated CML patients who contract COVID-19 are influenced by many factors. Tyrosine kinase inhibitor therapy may benefit CML patients due to its antiviral effect, but the interaction between TKIs and drugs used for COVID-19 treatment requires careful monitoring. An individual approach is needed in every case. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
